One less thing to worry about: The shrinking spectrum of tumors in BRCA founder mutation carriers

Journal of the National Cancer Institute

Volumn 96, Issue 1, 2004, Pages 2-3

  Garber, Judy E ^a   Sygnal, Sapna ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

BREAST CANCER; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; COWDEN SYNDROME; EDITORIAL; ENDOCRINE TUMOR; FAMILIAL CANCER; FAMILY HISTORY; FOUNDER EFFECT; GENE MUTATION; GENETIC DISTANCE; GENETIC SUSCEPTIBILITY; GERM LINE; HETEROZYGOTE; HUMAN; LUNG CANCER; MELANOMA; MUIR TORRE SYNDROME; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RETINOBLASTOMA; SOFT TISSUE SARCOMA;

EID: 0842302523     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh021     Document Type: Editorial

References (17)

1. Knudson AG Jr, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 1972;24:514-32.
2. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 1961;31:163-6.
3. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
4. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-6.
5. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
6. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
7. Foulkes WD, Bolduc N, Lambert D, Ginsburg O, Olien L, Yandell DW, et al. Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon. J Med Genet 1996;33: 534-9.
8. Phipps RF, Perry PM. Familial breast cancer and the association with colonic carcinoma. Eur J Surg Oncol 1989; 15:109-11.
9. Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern PG, Kushi LH. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history. Genet Epidemiol 1993;10:235-44.
10. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002;94:1221-6.
11. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
12. Thompson D, Easton DF: Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-65.
13. Gruber SB, Petersen GM. Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 2002;94:1344-5.
14. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 2004;96:15-21.
15. Kirchhoff T, Satagopan JM, Kauff ND, Huang H, Kolachana P, Palmer C, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst 2004;96:68-70.
16. Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am 2002;82:905-41.
17. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003;72:1308-14.